Treatment of Acute Vertigo

Mechanism and Efficacy of Each Medication

The American Academy of Otolaryngology-Head and Neck Surgery suggests that betahistine has no significant difference from placebo in reducing vertigo attacks in Ménière's disease patients over a 9-month treatment period, as found in the BEMED trial 1, 2
Prochlorperazine is a phenothiazine antiemetic with potent anti-vertigo properties that works centrally to control acute symptoms, and is more effective for immediate symptom control during acute vertigo attacks 3, 4
For acute vertigo episodes, medications with direct antiemetic and anti-vertigo effects like prochlorperazine are preferred over medications like betahistine that work through vascular mechanisms 3, 4

The American Academy of Otolaryngology-Head and Neck Surgery recommends prochlorperazine for acute vertigo attacks with severe symptoms requiring rapid relief, and when vertigo is accompanied by significant nausea and vomiting 3, 4
Prochlorperazine is suitable for short-term management of severe vertigo symptoms, and should be used with caution in elderly patients and those with cardiovascular disease 3, 4
Betahistine has a safety profile that includes common side effects such as headache, gastrointestinal symptoms, and occasionally nasopharyngitis, and should be used with caution in patients with asthma and peptic ulcer disease 6

For acute severe vertigo with nausea/vomiting, the first-line treatment is prochlorperazine for immediate symptom control, which can be administered via oral, IM, or IV routes based on severity 3, 4
After the acute phase has resolved, prochlorperazine should not be used for long-term management due to potential side effects, and betahistine may be considered for maintenance therapy to prevent recurrence, although its effectiveness should be regularly reassessed 3, 6

Failing to distinguish between different causes of vertigo which may respond differently to treatment, as emphasized by the American Academy of Otolaryngology-Head and Neck Surgery 5
Not considering the potential side effects of prochlorperazine, particularly in elderly patients, and the risk of tardive dyskinesia with prolonged use 3
Continuing betahistine indefinitely without reassessing its effectiveness, as its safety profile includes contraindications in patients with pheochromocytoma 6